🌟 Exciting News in Kidney Disease Management! 🌟
📚 Just Released: A Comprehensive Guidance Document on Chronic Kidney Disease (CKD) Management
🔍 Multinational population studies based on CKD-PC 2023 analyses highlight the incremental increase in the association of all CKD complications with worse categories of estimated glomerular filtration rate (eGFR) and albuminuria.
💡 Key Highlights:
-Emphasis on the importance of detecting CKD early, especially in high-risk populations.
-Recommendations for accurate assessment of GFR and urine albumin-to-creatinine ratio (ACR).
-Importance of using validated risk equations to estimate absolute risk of kidney failure.
-Comprehensive discussion on delaying CKD progression and managing complications.
-Insights into cardiovascular risk factor modification and drug stewardship in CKD.
-Optimal models of care, including the value of multidisciplinary teams and advanced care planning.
🔬 Newer data on treating hyperuricemia were evaluated, with no support for targeting hyperuricemia in the absence of symptoms.
📊 Tables provided for "expected" values for common laboratory tests by eGFR to aid in identifying aberrant values.
🚀 Conclusion: This guidance document offers exciting new approaches to CKD management, aiming to improve symptom management, disease modification, and person-centered care.
#KidneyDisease #CKDManagement #Healthcare #MedicalResearch #PatientCare #HealthTech #Nephrology #ChronicDiseaseManagement
It's here! The KDIGO 2024 CKD Guideline Executive Summary was released today in the April Issue of Kidney International (KI).
Read the Executive Summary in KI: https://lnkd.in/grYUb6mu
Download the PDF: https://lnkd.in/g9-UEiMX
The KDIGO 2024 CKD Guideline, based on the best current evidence, indicates exciting new approaches to management strategies and treatment options for people living with #CKD. The goal is to improve symptom management, disease modification, and person-centered approaches while also recognizing the heterogeneity of CKD. The fact that new therapies exist and others are being evaluated heralds an exciting time for people living with #kidney diseases.
Associate Professor at National University of Singapore. Secretary-General, Asian-Pacific Society of Hypertension. Secretary, Singapore Hypertension Society. Chief Investigator, Clinical Trials Section, Nephrology.
6moHonored to be cited several times for my work in the measurement and estimation of GFR in multiethnic populations for clinical practice and research. As my group had recommended 10 years ago, estimate GFR without consideration for ethnicity and use multiple biomarkers for accuracy in specialist practice or research. If you need accurate GFR, measure it.